Shares of Hims & Hers Health Inc (HIMS 20.27%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m.
Hims and Hers Health has acquired at-home lab testing facility Trybe Labs. The acquisition will allow the telehealth company to provide at-home lab testing through its platform.
Hims & Hers Health stock has surged 212% since my previous “buy” rating. Despite strong revenue and earnings growth expectations, I recommend holding off at the moment. Hims & Hers has consistently beat its revenue and earnings for the past several quarters, while the management has raised their forward expectations as a result of their Personalized solutions. However, the latest surge in the stock price is attributed to its provocative Super Bowl ad and favorable outlook on the regulatory landscape after RFK Jr.'s appointment as the Health Secretary.
There are a few stocks that come along every once in a while, arriving to change the way an old-fashioned industry works and operates. When investors get lucky enough to find one of them, it can typically bring on life-changing returns, even retiring them from active work if they choose to go that route.
Shares of Hims & Hers (HIMS -0.96%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the company's high short interest in this video.
In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS -1.85%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Hims & Hers Health's NYSE: HIMS share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers Health's stock price has attracted considerable attention from investors.
Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a blistering 490% over the past year alone.
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has surged an impressive 43% over the past week. A major driver of this growth was the company's widely discussed Super Bowl commercial, which aired on Sunday.